Cybin Inc.

Stocks

HELP

CA23256X4075

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
11.99 ^USD	+4.72%		+3.27%	+46.58%

08-14	Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-08	Certain Common Shares of Cybin Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026.	CI

Transcript : Cybin Inc. - Special Call

Published on 03/06/2026 at 10:43 am EST

S&P Capital IQ

Presenter Speech
Michael Cola (Executives)

Good morning, everyone, and thank you for taking the time today. I'm Mike Cola, CEO of Helus, and we're here today to discuss the results from our most recent

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Cybin Inc.

08-14	Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-08	Certain Common Shares of Cybin Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026.	CI
08-05	Helus Pharma Shares Rise After Appointing New CEO	MT
08-03	Helus Pharma Names Michael Halstead CEO	MT
08-03	Helus Pharma Announces Appointment of Michael Halstead as Chief Executive Officer, Effective August 3, 2026	CI
07-27	Wells Fargo Initiates Cybin at Overweight With CA$22.56 Price Target	MT
07-21	Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment	MT
07-21	Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder	CI
06-29	Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
06-25	Helus Pharma Closes $50 Million Underwritten Offering	MT
06-24	Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder	MT
06-24	Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress	CI
06-24	Helus Pharma Prices $50 Million Underwritten Offering	MT
04-30	Cybin Inc. will Change its Name to Helus Pharma	CI
04-28	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	CI